Home/Filings/3/0000899243-18-008659
3//SEC Filing

Novartis Institutes for BioMedical Research, Inc. 3

Accession 0000899243-18-008659

CIK 0001661998other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 6:25 PM ET

Size

6.5 KB

Accession

0000899243-18-008659

Insider Transaction Report

Form 3
Period: 2018-03-27
Holdings
  • Series B Preferred Stock

    Common Stock (1,979,226 underlying)
Footnotes (2)
  • [F1]The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
  • [F2]The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI.

Issuer

Homology Medicines, Inc.

CIK 0001661998

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001673852

Filing Metadata

Form type
3
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 6:25 PM ET
Size
6.5 KB